Lipocine Inc. — Q1 2017 Form 10-Q
Business context and period. Unaudited results for the three months ended March 31, 2017. Lipocine is a development-stage specialty pharmaceutical company focused on oral drug-delivery products, principally in men’s and women’s health. It has not generated product-sales revenue and depends on external financing to fund development.
Financial performance and position
| Metric | Q1 2017 | Q1 2016 / comparison |
|---|---|---|
| Revenue | None reported | None reported from product sales; filing reports no revenue for the quarter |
| Research and development expense | $3.08 million | $2.67 million; up $0.41 million (15%) |
| General and administrative expense | $1.83 million | $4.40 million; down $2.57 million (58%) |
| Total operating expenses / operating loss | $4.91 million | $7.07 million; expenses and operating loss down 31% |
| Net loss / loss per share | $4.86 million / $0.26 | $7.01 million / $0.38 |
| Cash used in operating activities | $3.14 million | $6.51 million |
| Cash and cash equivalents | $6.94 million at March 31 | $5.56 million at December 31, 2016 |
| Marketable securities | $19.86 million at March 31 | $21.28 million at December 31, 2016 |
| Current assets / current liabilities | $27.10 million / $2.34 million | Current ratio approximately 11.6x |
| Total liabilities / debt | $2.34 million / no debt reported | No credit facility or committed debt source |
Cash, cash equivalents and marketable securities totaled approximately $26.8 million at March 31, 2017, essentially unchanged from year-end. Net loss improved as lower G&A more than offset higher R&D. R&D growth primarily reflected $1.4 million of additional LPCN 1021 contract research costs, partly offset by lower technical-batch manufacturing and personnel costs. G&A fell mainly because pre-commercialization spending and personnel costs declined following 2016 restructurings. With no product revenue, gross margin is not applicable.
Material developments, outlook and risks
- LPCN 1021: The FDA issued a Complete Response Letter in June 2016 citing a mismatch between the proposed dosing algorithm and the Phase 3 trial regimen. The company was conducting two requested Phase 3 studies, the Dosing Validation and Dosing Flexibility studies; enrollment was complete by April 2017. Management expected top-line results in June 2017 and NDA resubmission in Q3 2017, subject to study results and FDA review. Approval is not assured.
- Other pipeline: LPCN 1111 was in Phase 2 development, with an FDA End-of-Phase-2 meeting anticipated in Q4 2017. LPCN 1107 was preparing for Phase 3; management planned to submit its protocol to the FDA via a Special Protocol Assessment in Q2 2017. Timelines and development costs remain uncertain.
- Funding and dilution: In March, Lipocine established a $20 million at-the-market equity program. By March 31 it had sold 666,853 shares for approximately $2.9 million gross and $2.7 million net proceeds. Management believed existing resources would fund projected operating requirements through March 31, 2018, but said additional capital would ultimately be needed. Funding may be unavailable or dilutive; cost overruns or delays could shorten the runway.
- Expected spending: Management estimated approximately $6.4 million of additional LPCN 1021 R&D costs for the DV and DF studies and manufacturing activities, and expected R&D expenses to rise as programs advance. It expects continuing operating losses.
- Legal and commitments: A securities class action was transferred to Utah; an amended complaint was filed April 27, 2017, after quarter-end. The company intended to move to dismiss and said it believed the claims were without merit. No litigation contingency was accrued because management did not consider any contingency probable and estimable. The Clarus patent-infringement case had been dismissed, but a patent interference remained pending. Operating-lease payments totaled $349,431 through 2018; other purchase commitments were generally cancellable.
- Other risks: Key risks include regulatory rejection or delay, clinical-trial outcomes, manufacturing and commercialization execution, competition in testosterone replacement, reimbursement and market acceptance, and the need for additional financing. The company reported effective disclosure controls and no material change in internal control over financial reporting.
Most important facts for investors to verify
- Actual DV and DF study results, subsequent NDA resubmission status, and FDA review requirements versus management’s stated timelines.
- Cash burn, remaining ATM capacity and shares issued, and whether financing is sufficient if development or regulatory timelines slip.
- Progress and expected funding needs for LPCN 1111 and LPCN 1107, including FDA feedback and Phase 3 plans.
- Developments in the securities class action and patent interference, and any change in potential financial exposure.
- Reconcile the filing’s share-count disclosure: its cover page states an “as of May 5, 2016” date despite this 2017 filing, so the date and applicable outstanding share count should be checked against the original filing.